Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

Drug companies still supplying Greece after ‘No’ vote

July 6, 2015
Life sciences
(Reuters) – Pharmaceutical companies said on Monday they would continue to supply medicines to Greece for now, despite increased financial uncertainty after Greeks rejected the terms of a rescue package from creditors in a referendum.
 
Drugmakers are owed more than 1.1 billion euros ($1.2 billion) by Greek hospitals and the state-run health insurer, after not being paid since December, but have promised to keep supplying the country on humanitarian grounds.
 
The European Federation of Pharmaceutical Industries and Associations (Efpia), representing 40 drug companies, said it stood by a commitment made last week to ensure supplies continued for the coming month.
 
Imports of life-saving medicines – along with fuel – top the list of products at risk as Greece struggles with bank closures and the threat of an exit from the euro zone. Nearly all Greek medicine is imported.
 
Efpia warned last week, however, that shortages could still emerge on the ground, given the fragmented nature of the Greek supply chain, adding this could be exacerbated if drugs were re-exported.
 
A spokeswoman for AstraZeneca said the company was preparing contingency plans but operations for now were continuing as normal.
 
“At present, there is no impact on our supply chain as, while the banks are closed, bank transfers to and within Greece are still possible,” she said.
 
Pfizer said current recorded stock levels in Greece should ensure that patients did not suffer any interruption in supply to its medicines in the short term.
 
Roche also said both its medicines and diagnostics were currently available to patients. “Roche is working to understand the full implications of yesterday’s referendum decision and will both review and take steps to revise its operating plans as needed,” the company said. 
 
By Ben Hirschler (Additional reporting by Paul Arnold in Zurich; Editing by Susan Fenton)

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Read more
April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Read more
April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

Read more
More news

How can we help you?

We're easy to reach